Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biocon Biologics Hails ‘Milestone’ Human Insulin Nod

Following EMA CHMP Positive Opinion For Inpremzia Biosimilar In Late February

Executive Summary

Biocon Biologics has welcomed the recent “milestone” positive opinion from the EMA’s CHMP for the Inpremzia biosimilar human insulin rival to Actrapid, on which it has partnered with Celerity Pharmaceuticals.

You may also be interested in...



Biocon Insulin Aspart US Opportunity: 'Not Completely Lost But Not The Best Situation'

Biocon may not be able to make it to the current contracting cycle in the US for its Viatris-partnered biosimilar aspart, but all is not lost, the management indicates. The Indian firm is also buoyant about the prospects of taking its franchise of potentially interchangeable recombinant human insulin to the US.

Biocon Insulin Aspart US Opportunity: 'Not Completely Lost But Not The Best Situation'

Biocon may not be able to make it to the current contracting cycle in the US for its Viatris-partnered biosimilar aspart, but all is not lost, the management indicates. The Indian firm is also buoyant about the prospects of taking its franchise of potentially interchangeable recombinant human insulin to the US.

Biosimilar Insulins Satisfy EMA’s CHMP

The EMA’s CHMP has issued positive opinions for two insulin biosimilars: Sanofi’s insulin aspart rival to NovoMix and Baxter’s insulin human (rDNA) version of Actrapid. At the same time, the CHMP has confirmed its recommendation to refuse marketing authorization for the Ipique ophthalmic version of bevacizumab.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151782

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel